Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced that its independently developed new drug Itapang® (Ivoxi Injection, PD-1/VEGF) has been approved for listing by the National Medicines Regulatory Authority of China (NMPA) in May 2024. The drug is the world's first bi-specific antibody for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSQ-NSCLC) that progresses after treatment with EGFR-TKI. THE APPROVAL OF IDAFANG® IS BASED ON A PHASE III CLINICAL STUDY CONDUCTED IN CHINA, WHICH DEMONSTRATED THE DRUG'S EFFICACY IN PROLONGING PROGRESSION-FREE SURVIVAL (PFS) AND TOTAL SURVIVAL (OS). Lung cancer has high morbidity rates and high mortality rates worldwide, and EGFR mutations are the predominant mutation type in Chinese NSCLC patients. IDAFANG® offers a new treatment option to meet the needs of patients with advanced drug resistance. Kangfang Bio reminds investors to exercise caution when buying and selling company shares.

Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced that its independently developed new drug Itapang® (Ivoxi Injection, PD-1/VEGF) has been approved for listing by the National Medicines Regulatory Authority of China (NMPA) in May 2024. The drug is the world's first bi-specific antibody for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSQ-NSCLC) that progresses after treatment with EGFR-TKI. THE APPROVAL OF IDAFANG® IS BASED ON A PHASE III CLINICAL STUDY CONDUCTED IN CHINA, WHICH DEMONSTRATED THE DRUG'S EFFICACY IN PROLONGING PROGRESSION-FREE SURVIVAL (PFS) AND TOTAL SURVIVAL (OS). Lung cancer has high morbidity rates and high mortality rates worldwide, and EGFR mutations are the predominant mutation type in Chinese NSCLC patients. IDAFANG® offers a new treatment option to meet the needs of patients with advanced drug resistance. Kangfang Bio reminds investors to exercise caution when buying and selling company shares.